Cardiomyopathy syndrome in Atlantic salmon Salmo salar L.: A review of the current state of knowledge

• Published in: Journal of Fish Diseases
• Main Authors: Garseth, Å H, Fritsvold, C, Svendsen, J C, Bang Jensen, B, Mikalsen, A B
• Other Authors: The Norwegian Seafood Research Fund (FHF)
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2017
• Subjects: Faroe Islands; Norway; Atlantic salmon; Salmo salar
• Online Access: http://dx.doi.org/10.1111/jfd.12735; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjfd.12735; https://onlinelibrary.wiley.com/doi/pdf/10.1111/jfd.12735

Abstract Cardiomyopathy syndrome ( CMS ) is a severe cardiac disease affecting Atlantic salmon Salmo salar L. The disease was first recognized in farmed Atlantic salmon in Norway in 1985 and subsequently in farmed salmon in the Faroe Islands, Scotland and Ireland. CMS has also been described in wild Atlantic salmon in Norway. The demonstration of CMS as a transmissible disease in 2009, and the subsequent detection and initial characterization of piscine myocarditis virus ( PMCV ) in 2010 and 2011 were significant discoveries that gave new impetus to the CMS research. In Norway, CMS usually causes mortality in large salmon in ongrowing and broodfish farms, resulting in reduced fish welfare, significant management‐related challenges and substantial economic losses. The disease thus has a significant impact on the Atlantic salmon farming industry. There is a need to gain further basic knowledge about the virus, the disease and its epidemiology, but also applied knowledge from the industry to enable the generation and implementation of effective prevention and control measures. This review summarizes the currently available, scientific information on CMS and PMCV with special focus on epidemiology and factors influencing the development of CMS .